Back to results
US 2023/0145003 A1Published application
Compounds and uses thereof
AssigneeFoghorn Therapeutics Inc.
InventorsKevin J. WILSON, Shawn E.R. SCHILLER, Solymar NEGRETTI
Life of this patent
Estimating the term…
Abstract
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
Claims58
A compound having the structure:
- wherein
- A is
- m is 0, 1, 2, or 3;
- n is 1 or 2;
- o is 0 or 1;
- X is O, CH2, or NR7;
- X′ is N, CH, or CRX, wherein RX is a halogen;
- B is an optionally substituted 6-membered monocyclic heteroarylene or an optionally substituted 9- or 10-membered bicyclic heteroarylene;
- L is a covalent bond, optionally substituted C1-C3 alkylene, C2 alkynylene, optionally substituted C2 alkenylene, optionally substituted C2-C3 heteroalkylene, optionally substituted C3-C5 cycloalkylene, or optionally substituted 4- to 10-membered heterocyclylene;
- C is optionally substituted 3- to 10-membered cycloalkyl;
- optionally substituted 6- to 10-membered aryl;
- optionally substituted 5- to 10-membered heteroaryl;
- or optionally substituted 5- to 10-membered heterocyclyl;
- R1 and R7 are, independently, hydrogen or optionally substituted C1-C6 alkyl;
- each R2 and R3 is independently, hydrogen, optionally substituted C1-C6 alkyl;
- or
- optionally substituted C1-C6 heteroalkyl;
- R4 is cyano, fluoro, hydroxy, or —CH2OH;
- R5 is C1-C3 alkyl optionally substituted with one, two, three, four, five, six, or seven fluoro groups;
- and
- R6 is C1-C3 alkyl optionally substituted with one, two, three, four, five, six, or seven fluoro groups,
- or a pharmaceutically acceptable salt thereof.
19 more elements
(canceled)
(canceled)
(canceled)
(canceled)
-26. (canceled)
(canceled)
-47. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-76. (canceled)
(canceled)
(canceled)
-89. (canceled)
-115. (canceled)
Dependencies are inferred from the claim text.